Division of Diabetes, Endocrinology and Gastroenterology, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, U.K.
Division of Cardiovascular Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, U.K.
Diabetes Care. 2021 Aug;44(8):1835-1841. doi: 10.2337/dc20-2797. Epub 2021 Jun 18.
Impaired rate-dependent depression of the Hoffman reflex (HRDD) is a marker of spinal inhibitory dysfunction and has previously been associated with painful neuropathy in a proof-of-concept study in patients with type 1 diabetes. We have now undertaken an assessment of HRDD in patients with type 1 or type 2 diabetes.
A total of 148 participants, including 34 healthy control subjects, 42 patients with painful diabetic neuropathy, and 62 patients with diabetic neuropathy without pain, underwent an assessment of HRDD and a detailed assessment of peripheral neuropathy, including nerve conduction studies, corneal confocal microscopy, and thermal threshold testing.
Compared with healthy control subjects ( < 0.001) and patients without pain ( < 0.001), we found that HRDD is impaired in patients with type 1 or type 2 diabetes with neuropathic pain. These impairments are unrelated to diabetes type and the presence or severity of neuropathy. In contrast, patients without neuropathic pain ( < 0.05) exhibited enhanced HRDD compared with control subjects.
We suggest that loss or impairment of HRDD may help to identify a subpopulation of patients with painful diabetic neuropathy mediated by impaired spinal inhibitory systems who may respond optimally to therapies that target spinal or supraspinal mechanisms. Enhanced RDD in patients without pain may reflect engagement of spinal pain-suppressing mechanisms.
Hoffman 反射(HRDD)的速率依赖性抑制减弱是脊髓抑制功能障碍的标志物,先前在 1 型糖尿病患者的概念验证研究中与痛性神经病变相关。我们现在对 1 型或 2 型糖尿病患者的 HRDD 进行了评估。
共有 148 名参与者,包括 34 名健康对照者、42 名痛性糖尿病神经病变患者和 62 名无痛性糖尿病神经病变患者,他们接受了 HRDD 评估和外周神经病变的详细评估,包括神经传导研究、角膜共聚焦显微镜检查和温度阈值测试。
与健康对照组(<0.001)和无痛患者(<0.001)相比,我们发现有痛性神经病变的 1 型或 2 型糖尿病患者的 HRDD 受损。这些损害与糖尿病类型和周围神经病变的存在或严重程度无关。相比之下,无痛患者(<0.05)的 HRDD 增强,与对照组相比。
我们认为,HRDD 的丧失或受损可能有助于识别痛性糖尿病神经病变的亚群,这些患者的脊髓抑制系统受损,可能对靶向脊髓或脊髓上机制的治疗反应最佳。无痛患者的增强 RDD 可能反映了脊髓疼痛抑制机制的参与。